FY2025 · ended Dec 31, 2025 · Revenue $521.31M, +54.7% YoY · Filed Feb 25, 2026
Mirum Pharmaceuticals, Inc. (MIRM) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $521.3 million and a net loss of $23.4 million. Free cash flow was $54.9 million. As of Sep 30, 2026 it held $500.5 million in cash and investments and $12.3 million in total debt.
Revenue (TTM)
$670.78M
+42.2% vs year-ago TTM
Net income (TTM)
$-903.88M
-2082.1% vs year-ago TTM
Operating cash flow (TTM)
$-271.26M
-707.0% vs year-ago TTM
Free cash flow (TTM)
$-273.85M
-717.9% vs year-ago TTM
EPS (TTM)
$-15.11
-1700.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
60.34M
+23.1% vs prior year
Net cash
$488.14M
as of Sep 30, 2026
Operating margin
-133.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MIRM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Foster City, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1759425
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $521.3M | $336.9M | $186.4M | $77.1M | $19.1M |
| Operating income | -$22.1M | -$87.6M | -$109.2M | -$131.2M | -$173.4M |
| Net income | -$23.4M | -$87.9M | -$163.4M | -$135.7M | -$84.0M |
| Diluted EPS | -$0.47 | -$1.85 | -$4.00 | -$4.02 | — |
| Operating cash flow | $55.8M | $10.3M | -$70.9M | -$120.1M | -$132.8M |
| Free cash flow | $54.9M | $9.3M | -$71.1M | -$120.4M | -$132.8M |
| Total assets | $842.8M | $670.8M | $646.6M | $352.9M | $294.7M |
| Total liabilities | $528.1M | $445.1M | $398.0M | $210.9M | $174.4M |
| Stockholders' equity | $314.7M | $225.6M | $248.7M | $142.0M | $120.2M |
| Cash and investments | $391.4M | $292.8M | $286.3M | $151.7M | $161.5M |
| Total debt | $9.7M | $9.7M | $1.7M | $2.2M | $2.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Other events
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 12, 2026 |
| 8-K |
Current report
Other events
|
Sep 28, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 8, 2026 | Sep 2, 2026 |
All 674 Mirum Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.